Gefitinib decreases the synthesis of matrix metalloproteinase and the adhesion to extracellular matrix proteins of colon cancer cells

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 129-134

  Toda, Daisaku ^a   Ota, Tetsuya ^a   Tsukuda, Kazunori ^a   Watanabe, Keitaro ^a   Fujiyama, Toshiyuki ^a   Murakami, Masakazu ^a   Naito, Minoru ^a   Shimizu, Nobuyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Adhesion; Colon cancer cell line; ECM; Gefitinib; MMP; RT PCR

Indexed keywords

COLLAGEN TYPE 4; GEFITINIB; LAMININ; MATRIX METALLOPROTEINASE; MESSENGER RNA; SCLEROPROTEIN;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL STRAIN HT29; COLON CANCER; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LOW DRUG DOSE; METASTASIS; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL GROWTH PROCESSES; COLONIC NEOPLASMS; EXTRACELLULAR MATRIX PROTEINS; HT29 CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; QUINAZOLINES;

EID: 32144447824     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Murray T, Ward E et al: Cancer statistics. CA Cancer J Clin 55: 10-30, 2005.
2. Khazaie K, Schirrmacher V and Lichtner RB: EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12: 255-274, 1993.
3. Messa C, Russo F, Caruso MG and Di Leo A: EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 37: 285-289, 1998.
4. Kitadai Y, Ellis LM, Tucker SL et al: Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 149: 1541-1551, 1996.
5. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250, 1999.
6. Mackenzie MJ, Hirte HW, Glenwood G et al: A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 23: 165-170, 2005.
7. Huang SM, Li J and Harari PM: Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 1: 507-514, 2002.
8. Zhang B, Wu KF, Cao ZY et al: IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression. Leuk Res 28: 91-95, 2004.
9. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
10. Carpenter G and Cohen S: Epidermal growth factor. J Biol Chem 265: 7709-7712, 1990.
11. Radinsky R, Risin S, Fan D et al: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer 1: 19-31, 1995.
12. Huang SM, Li J and Harari PM: Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 1: 507-514, 2002.
13. Pichard V, Honore S, Kovacic H et al: Adhesion, actin cytoskeleton organisation and the spreading of colon adenocarcinoma cells induced by EGF are mediated by alpha2beta1 integrin low clustering through focal adhesion kinase. Histochem Cell Biol 116: 337-348, 2001.
14. Kim WH, Jun SH, Kibbey MC et al: Expression of beta 1 integrin in laminin-adhesion-selected human colon cancer cell lines of varying tumorigenicity. Invas Metastasis 14: 147-155, 1994.
15. Shintani S, Li C, Mihara M et al: Gefitinib ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. Cancer Lett 201: 149-155, 2003.
16. Sawhney RS, Sharma B, Humphrey LE et al: Integrin alpha2 and extracellular signal-regulated kinase are functionally linked in highly malignant autocrine transforming growth factor-alpha-driven colon cancer cells. J Biol Chem 278: 19861-19869, 2003.
17. Papadopoulou S, Scorilas A, Arnogianaki N et al: Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumour Biol 22: 383-389, 2001.
18. Matsuyama Y, Takao S and Aikou T: Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 80: 105-110, 2002.
19. Murray D, Morrin M and McDonnell S: Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res 24: 489-494, 2004.
20. Kubiatowski T, Jang T, Lachyankar MB et al: Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas. J Neurosurg 95: 480-488, 2001.
21. Matsuo M, Sakurai H and Saiki I: ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2: 557-561, 2003.
22. Liu Z and Klominek J: Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors. Neoplasia 6: 705-712, 2004.
23. Cohen MH, Williams GA, Sridhara R et al: United States Food and Drug Administration Drug Approval Summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10: 1212-1218, 2004.